Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology

Keming Lin,Baijin Xia,Xuemei Wang,Xin He,Mo Zhou,Yingtong Lin,Yidan Qiao,Rong Li,Qier Chen,Yuzhuang Li,Jinzhu Feng,Tao Chen,Cancan Chen,Xinyu Li,Hui Zhang,Lijuan Lu,Bingfeng Liu,Xu Zhang
DOI: https://doi.org/10.1186/s12967-024-05159-x
IF: 8.44
2024-04-14
Journal of Translational Medicine
Abstract:Chimeric antigen receptor T (CAR-T) cell therapy, as an emerging anti-tumor treatment, has garnered extensive attention in the study of targeted therapy of multiple tumor-associated antigens in hepatocellular carcinoma (HCC). However, the suppressive microenvironment and individual heterogeneity results in downregulation of these antigens in certain patients' cancer cells. Therefore, optimizing CAR-T cell therapy for HCC is imperative.
medicine, research & experimental
What problem does this paper attempt to address?